CCRM
Nish Patel PhD serves as the Development Manager for Cell and Gene Therapy at CCRM since December 2021, following a distinguished tenure as Senior Research Associate at The Hospital for Sick Children from November 2013 to December 2021, where responsibilities included managing a substantial laboratory budget and designing research projects in systems biology and pharmacology. Previous experience encompasses research positions at the University of Toronto and Harvard Medical School, focusing on synthetic antibodies for cancer treatment and drug resistance biomarkers. Holding a Ph.D. in Physiology from the University of Toronto, Nish Patel's academic background includes a B.Sc. Honours in Physiology from Victoria University, also part of the University of Toronto.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.